Defenders of drug patents have for years claimed the need for patents and high drug prices because of the high cost of developing new drugs. But in fact a large part of the cost of new drug development is funded by the government (that is, taxpayers), and according to a study published in “JAMA Network Open”, there is no correlation between R&D costs and high drug prices. The researchers compared the cost of developing a new drug with its selling price and found no correlation, nor was the therapeutic value of the drug related to price. The researchers found that pharmaceutical companies did not price the drug based on the cost or quality of the drug’s development, but on what the market could afford .
This article is reprinted from: https://www.solidot.org/story?sid=73004
This site is for inclusion only, and the copyright belongs to the original author.